JP7012075B2 - 眼瞼炎の治療に使用するための医薬組成物 - Google Patents

眼瞼炎の治療に使用するための医薬組成物 Download PDF

Info

Publication number
JP7012075B2
JP7012075B2 JP2019515654A JP2019515654A JP7012075B2 JP 7012075 B2 JP7012075 B2 JP 7012075B2 JP 2019515654 A JP2019515654 A JP 2019515654A JP 2019515654 A JP2019515654 A JP 2019515654A JP 7012075 B2 JP7012075 B2 JP 7012075B2
Authority
JP
Japan
Prior art keywords
treatment
anterior
pharmaceutical composition
blepharitis
posterior blepharitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019515654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532931A5 (enExample
JP2019532931A (ja
Inventor
ベルンハルト グンター，
フランク ルッシャー，
ソンニャ クレッサー，
Original Assignee
ノバリック ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバリック ゲーエムベーハー filed Critical ノバリック ゲーエムベーハー
Publication of JP2019532931A publication Critical patent/JP2019532931A/ja
Publication of JP2019532931A5 publication Critical patent/JP2019532931A5/ja
Application granted granted Critical
Publication of JP7012075B2 publication Critical patent/JP7012075B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019515654A 2016-09-22 2017-09-20 眼瞼炎の治療に使用するための医薬組成物 Active JP7012075B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16190138 2016-09-22
EP16190138.4 2016-09-22
PCT/EP2017/073697 WO2018054932A1 (en) 2016-09-22 2017-09-20 Pharmaceutical compositions for use in the therapy of blepharitis

Publications (3)

Publication Number Publication Date
JP2019532931A JP2019532931A (ja) 2019-11-14
JP2019532931A5 JP2019532931A5 (enExample) 2020-11-05
JP7012075B2 true JP7012075B2 (ja) 2022-01-27

Family

ID=56990295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019515654A Active JP7012075B2 (ja) 2016-09-22 2017-09-20 眼瞼炎の治療に使用するための医薬組成物

Country Status (11)

Country Link
US (1) US11684589B2 (enExample)
EP (1) EP3515420B1 (enExample)
JP (1) JP7012075B2 (enExample)
KR (1) KR102614858B1 (enExample)
CN (2) CN109890374A (enExample)
AU (1) AU2017329772B2 (enExample)
CA (1) CA3036297C (enExample)
ES (1) ES2969758T3 (enExample)
MX (1) MX2019003363A (enExample)
PL (1) PL3515420T3 (enExample)
WO (1) WO2018054932A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
MX363182B (es) 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
EP2895144B1 (en) 2012-09-12 2017-01-11 Novaliq GmbH Semifluorinated alkane compositions
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
EP3722274B1 (en) 2015-09-30 2023-06-07 Novaliq GmbH 2-perfluorobutyl pentane for ophthalmic administration
DK3442480T3 (da) 2016-06-23 2020-01-13 Novaliq Gmbh Fremgangsmåde til topisk indgivelse
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
MX381639B (es) 2016-12-23 2025-03-13 Novaliq Gmbh Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
JP7814839B2 (ja) 2017-09-27 2026-02-17 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
AU2019246035B2 (en) 2018-03-28 2024-07-18 Novaliq Gmbh Pharmaceutical composition comprising timolol
JP7855312B2 (ja) 2018-04-27 2026-05-08 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
EP3852734A1 (en) * 2018-09-22 2021-07-28 Novaliq GmbH Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
CN114449999A (zh) 2019-09-06 2022-05-06 诺瓦利克有限责任公司 用于治疗葡萄膜炎的眼用组合物
EP3861857A1 (en) * 2020-02-07 2021-08-11 Novaliq GmbH Antiparasitic compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515494A (ja) 2008-03-26 2011-05-19 エリック ドネンフェルド， テトラサイクリンファミリー抗生物質を用いる、眼瞼縁および涙液膜機能の改善ならびに眼瞼縁疾患の処置のための方法
JP2013513586A (ja) 2009-12-14 2013-04-22 ノバリック ゲーエムベーハー ドライアイ症候群の治療のための医薬組成物
JP2015527386A (ja) 2012-09-12 2015-09-17 ノバリック ゲーエムベーハー 半フッ素化アルカン組成物
JP2015531344A (ja) 2012-09-12 2015-11-02 ノバリック ゲーエムベーハー 半フッ化アルカンの混合物を含む組成物

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
US4452818A (en) 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
US5370313A (en) 1994-01-10 1994-12-06 Beard; Walter C. Sterile liquid dispenser
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
IN184589B (enExample) 1996-10-16 2000-09-09 Alza Corp
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US6645963B2 (en) 1997-11-05 2003-11-11 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
CA2278328C (en) 1998-02-09 2008-07-22 Macrochem Corporation Antifungal nail lacquer and method using same
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
CN1221249C (zh) 1998-08-19 2005-10-05 斯凯伊药品加拿大公司 普鲁泊福的可注射水分散体
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
EP1152749B1 (en) 1999-02-08 2006-04-12 ALZA Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
WO2000054588A1 (en) 1999-03-15 2000-09-21 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (de) 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
JP2001158734A (ja) 1999-12-02 2001-06-12 Lion Corp 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
DE10024413A1 (de) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
WO2002089849A1 (en) 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
US20040265362A1 (en) 2001-09-04 2004-12-30 Rudy Susilo Plaster for the treatment of dysfunctions and disorders of nail growth
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
EP1663148A2 (en) 2003-08-25 2006-06-07 Foamix Ltd. Penetrating pharmaceutical foam
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
CA2538856C (en) 2003-10-10 2010-06-29 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
CA2540621A1 (en) 2003-11-19 2005-06-09 Barnes-Jewish Hospital Enhanced drug delivery
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
US20080019926A1 (en) 2004-04-19 2008-01-24 Marie-Pierre Krafft Lung Surfactant Supplements
EP1763336A1 (en) 2004-06-08 2007-03-21 Ocularis Pharma, Inc. Hydrophobic ophthalmic compositions and methods of use
US7063241B2 (en) 2004-06-10 2006-06-20 Allergan, Inc. Dispensing tip
AU2005262392A1 (en) 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
BRPI0614084A2 (pt) 2005-08-05 2011-03-09 Bharat Serums And Vaccines Limited composição estável de emulsão de óleo-em-água de propofol, administrável por via intranovesa; e processo de preparação de uma composição
FR2892023B1 (fr) 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102005055811A1 (de) 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2008011836A2 (es) 2006-07-25 2008-01-31 Osmotica Corp. Soluciones oftálmicas
US20080089923A1 (en) 2006-09-29 2008-04-17 Burkstrand Michael J Biodegradable ocular implants and methods for treating ocular conditions
KR20090087917A (ko) 2006-12-07 2009-08-18 썬 파마 어드밴스트 리서치 컴패니 리미티드 마이크로리터량의 액체를 방울의 형태로 분배하기 위한 계량된 방울 병
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
PL2110126T3 (pl) 2008-04-18 2012-04-30 Novaliq Gmbh Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej
US20100006600A1 (en) 2008-07-14 2010-01-14 Dascanio Gustavo A Fluid dispenser including hydrophobic ring
JP2012509737A (ja) 2008-11-26 2012-04-26 サーモディクス，インコーポレイティド 埋め込み式の眼薬送達器具および眼薬送達方法
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
JP5736635B2 (ja) 2009-06-25 2015-06-17 ライオン株式会社 ドライアイ治療剤
JP5549669B2 (ja) 2009-06-25 2014-07-16 ライオン株式会社 眼科用組成物、ドライアイ治療剤及びビタミンａの安定化方法
PT2387391T (pt) 2009-07-24 2017-04-20 Mika Pharma Ges Für Die Entw Und Vermarktung Pharmazeutischer Produkte Mbh Processo para o desenvolvimento de uma composição líquida a ser aplicada na forma de espuma sobre a pele e composição de aplicação tópica
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
DE102010022567A1 (de) 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
EP2661280B1 (en) 2011-01-04 2018-11-21 Novaliq GmbH O/w-emulsions comprising semifluorinated alkanes
CN103561724B (zh) 2011-05-25 2016-06-29 诺瓦利克有限责任公司 给药给甲的药物组合物
JP6039145B2 (ja) 2011-05-25 2016-12-07 ノバリック ゲーエムベーハー 半フッ化アルカンを基礎にした局所薬学的組成物
PT2806886T (pt) 2012-01-23 2017-03-24 Novaliq Gmbh Composições de proteínas estabilizadas baseadas em alcanos semifluorados
WO2013126602A1 (en) 2012-02-21 2013-08-29 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
MX376125B (es) 2014-03-31 2025-03-07 Amcor Rigid Plastics Usa Llc Recipiente de liberacion controlada.
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
WO2016025560A1 (en) 2014-08-13 2016-02-18 University Of Florida Research Foundation, Inc. Preservative removal from eye drops
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
EP3722274B1 (en) 2015-09-30 2023-06-07 Novaliq GmbH 2-perfluorobutyl pentane for ophthalmic administration
JP2019517580A (ja) 2016-06-01 2019-06-24 ハロルド・リチャード・ヘルストロムＨａｒｏｌｄ Ｒｉｃｈａｒｄ ＨＥＬＬＳＴＲＯＭ 副交感神経薬および抗交感神経薬でのドライアイ疾患の処置
DK3442480T3 (da) 2016-06-23 2020-01-13 Novaliq Gmbh Fremgangsmåde til topisk indgivelse
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
CN109803650A (zh) 2016-09-28 2019-05-24 诺瓦利克有限责任公司 包含大麻素受体结合配体的组合物
WO2018114557A1 (en) 2016-12-22 2018-06-28 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
MX381639B (es) 2016-12-23 2025-03-13 Novaliq Gmbh Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
US20210069014A1 (en) 2017-05-06 2021-03-11 Novaliq Gmbh Drop dispenser
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
JP7814839B2 (ja) 2017-09-27 2026-02-17 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
AU2019246035B2 (en) 2018-03-28 2024-07-18 Novaliq Gmbh Pharmaceutical composition comprising timolol
JP7855312B2 (ja) 2018-04-27 2026-05-08 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
EP3852734A1 (en) 2018-09-22 2021-07-28 Novaliq GmbH Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
CN113164609A (zh) 2018-11-27 2021-07-23 诺瓦利克有限责任公司 包含ω-3脂肪酸乙酯的半氟化烷烃组合物
CN113518619A (zh) 2019-01-21 2021-10-19 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的药物组合物
WO2020239646A1 (en) 2019-05-24 2020-12-03 Novaliq Gmbh Ophthalmic composition for the treatment of ocular allergy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515494A (ja) 2008-03-26 2011-05-19 エリック ドネンフェルド， テトラサイクリンファミリー抗生物質を用いる、眼瞼縁および涙液膜機能の改善ならびに眼瞼縁疾患の処置のための方法
JP2013513586A (ja) 2009-12-14 2013-04-22 ノバリック ゲーエムベーハー ドライアイ症候群の治療のための医薬組成物
JP2015527386A (ja) 2012-09-12 2015-09-17 ノバリック ゲーエムベーハー 半フッ素化アルカン組成物
JP2015531344A (ja) 2012-09-12 2015-11-02 ノバリック ゲーエムベーハー 半フッ化アルカンの混合物を含む組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
European Journal of Pharmaceutics and Biopharmaceutics，2014年，88，pp.123-128
Journal of Ocular Pharmacology and Therapeutics，2015年，31(8)，pp.498-503
Survey of Ophthalmology，2007年，52(3)，pp.289-299
The Ocular Surface，2014年，12(4)，pp.273-284
眼瞼炎－１７．眼疾患－ＭＳＤマニュアル プロフェッショナル版，2016年07月，https://www.msdmanuals.com/ja-jp/プロフェッショナル/17-眼疾患/眼瞼および流涙疾患/眼瞼炎（令和３年５月２４日検索）

Also Published As

Publication number Publication date
CA3036297C (en) 2023-09-05
US20190274970A1 (en) 2019-09-12
EP3515420C0 (en) 2023-11-08
AU2017329772A1 (en) 2019-04-04
PL3515420T3 (pl) 2024-04-08
EP3515420A1 (en) 2019-07-31
KR102614858B1 (ko) 2023-12-18
CN116172987A (zh) 2023-05-30
AU2017329772B2 (en) 2023-02-02
US11684589B2 (en) 2023-06-27
CN109890374A (zh) 2019-06-14
WO2018054932A1 (en) 2018-03-29
CA3036297A1 (en) 2018-03-29
ES2969758T3 (es) 2024-05-22
KR20190057324A (ko) 2019-05-28
JP2019532931A (ja) 2019-11-14
EP3515420B1 (en) 2023-11-08
MX2019003363A (es) 2019-10-02

Similar Documents

Publication Publication Date Title
KR102614858B1 (ko) 안검염 치료에 사용되는 약제학적 조성물
AU2019358249B2 (en) Ophthalmic composition for treatment of dry eye disease
AU2017384650B2 (en) Ophthalmic composition for treatment of dry eye disease
Holzchuh et al. Clinical treatment of ocular Demodex folliculorum by systemic ivermectin
TWI650122B (zh) 用於預防及／或治療乾眼症之組成物、方法及／或裝置
JP2019532931A5 (enExample)
KR20210127197A (ko) 4-(7-히드록시-2-이소프로필-4-옥소-4h-퀴나졸린-3-일)-벤조니트릴의 제형
CN114096244A (zh) 治疗眼病
US20170239307A1 (en) Composition of doxycycline in liposomes for the prevention, improvement and/or treatment of ocular pathologies
Hakim et al. Medical management of blepharitis
RU2850452C2 (ru) Способы лечения боли на поверхности глаза
RU2828769C2 (ru) Офтальмологические композиции для лечения синдрома сухого глаза
HK40009131A (en) Pharmaceutical compositions for use in the therapy of blepharitis
HK40113015A (en) Ophthalmic composition for treatment of dry eye disease
HK40114301A (en) Ophthalmic composition for treatment of dry eye disease
HK40058504B (en) Ophthalmic composition for treatment of dry eye disease
HK40058504A (en) Ophthalmic composition for treatment of dry eye disease
Karpecki et al. Making Strides in Blepharitis Treatment
HK40000392B (en) Ophthalmic composition for treatment of dry eye disease
HK40000392A (en) Ophthalmic composition for treatment of dry eye disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200916

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220117

R150 Certificate of patent or registration of utility model

Ref document number: 7012075

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250